

# Joan ClÀria

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9256449/publications.pdf>

Version: 2024-02-01

158  
papers

17,212  
citations

18482

62  
h-index

14759

127  
g-index

163  
all docs

163  
docs citations

163  
times ranked

24338  
citing authors

#	ARTICLE	IF	CITATIONS
1	Essential lipid autacoids rewire mitochondrial energy efficiency in metabolic dysfunction-associated fatty liver disease. <i>Hepatology</i> , 2023, 77, 1303-1318.	7.3	10
2	Mitochondrial dysfunction governs immunometabolism in leukocytes of patients with acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2022, 76, 93-106.	3.7	51
3	Albumin Lipidomics Reveals Meaningful Compositional Changes in Advanced Cirrhosis and Its Potential to Promote Inflammation Resolution. <i>Hepatology Communications</i> , 2022, 6, 1443-1456.	4.3	6
4	Reduced Plasma Extracellular Vesicle CD5L Content in Patients With Acute-On-Chronic Liver Failure: Interplay With Specialized Pro-Resolving Lipid Mediators. <i>Frontiers in Immunology</i> , 2022, 13, 842996.	4.8	11
5	Hepatic inflammasome activation as origin of Interleukin-1 $\beta$ and Interleukin-1 $\gamma$ in liver cirrhosis. <i>Gut</i> , 2021, 70, 1799-1800.	12.1	14
6	Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation. <i>Gut</i> , 2021, 70, gutjnl-2019-320170.	12.1	47
7	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 1097-1108.	3.7	149
8	Assessing the role of amino acids in systemic inflammation and organ failure in patients with ACLF. <i>Journal of Hepatology</i> , 2021, 74, 1117-1131.	3.7	45
9	The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 670-685.	3.7	204
10	Albumin protects the liver from tumor necrosis factor $\alpha$ -induced immunopathology. <i>FASEB Journal</i> , 2021, 35, e21365.	0.5	15
11	Untargeted lipidomics uncovers lipid signatures that distinguish severe from moderate forms of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 75, 1116-1127.	3.7	31
12	Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. <i>Journal of Hepatology</i> , 2021, 75, S49-S66.	3.7	146
13	Leveraging omics to understand the molecular basis of acute-on-chronic liver failure. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2021, .	0.2	0
14	Proresolving lipid mediators and liver disease. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2021, 1866, 159023.	2.4	11
15	Mitochondrial Dysfunction in Advanced Liver Disease: Emerging Concepts. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 772174.	3.5	9
16	La aplicaci3n de las 3micas para comprender la base molecular de la insuficiencia hep3tica aguda sobre cr3nica. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2021, 2, 528-540.	0.2	0
17	Efficacy of Albumin Treatment for Patients with CirrhosisAndInfections Unrelated to Spontaneous BacterialAPeritonitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 963-973.e14.	4.4	77
18	Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. <i>Journal of Hepatology</i> , 2020, 72, 688-701.	3.7	223

#	ARTICLE	IF	CITATIONS
19	Anti-Inflammatory and Proresolving Effects of the Omega-6 Polyunsaturated Fatty Acid Adrenic Acid. <i>Journal of Immunology</i> , 2020, 205, 2840-2849.	0.8	33
20	Albumin internalizes and inhibits endosomal TLR signaling in leukocytes from patients with decompensated cirrhosis. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	47
21	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020, 73, 842-854.	3.7	282
22	Interleukin-22 in acute-on-chronic liver failure: A matter of ineffective levels, receptor dysregulation or defective signalling?. <i>Journal of Hepatology</i> , 2020, 73, 980-982.	3.7	8
23	Resolvin E1 derived from eicosapentaenoic acid prevents hyperinsulinemia and hyperglycemia in a host genetic manner. <i>FASEB Journal</i> , 2020, 34, 10640-10656.	0.5	43
24	Stimulation of soluble guanylate cyclase exerts antiinflammatory actions in the liver through a VASP/NF- $\kappa$ B/NLRP3 inflammasome circuit. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 28263-28274.	7.1	31
25	Leukocytes, Systemic Inflammation and Immunopathology in Acute-on-Chronic Liver Failure. <i>Cells</i> , 2020, 9, 2632.	4.1	65
26	Macrophage Activation Markers, CD163 and CD206, in Acute-on-Chronic Liver Failure. <i>Cells</i> , 2020, 9, 1175.	4.1	89
27	Albumin in decompensated cirrhosis: new concepts and perspectives. <i>Gut</i> , 2020, 69, 1127-1138.	12.1	190
28	The Role of Macrophage-Inducible C-Type Lectin in Different Stages of Chronic Liver Disease. <i>Frontiers in Immunology</i> , 2020, 11, 1352.	4.8	13
29	HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure. <i>Journal of Hepatology</i> , 2020, 73, 113-120.	3.7	58
30	Genetic variants of innate immunity receptors are associated with mortality in cirrhotic patients with bacterial infection. <i>Liver International</i> , 2020, 40, 646-653.	3.9	10
31	Targeted lipidomics reveals extensive changes in circulating lipid mediators in patients with acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2020, 73, 817-828.	3.7	48
32	Characterization of Blood Immune Cells in Patients With Decompensated Cirrhosis Including ACLF. <i>Frontiers in Immunology</i> , 2020, 11, 619039.	4.8	39
33	Liver Failure, Acute-on-Chronic. , 2020, , 436-443.		1
34	Pathophysiological role of prostanoids in coagulation of the portal venous system in liver cirrhosis. <i>PLoS ONE</i> , 2019, 14, e0222840.	2.5	7
35	Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis. <i>Gastroenterology</i> , 2019, 157, 149-162.	1.3	178
36	Leukocytes from obese individuals exhibit an impaired SPM signature. <i>FASEB Journal</i> , 2019, 33, 7072-7083.	0.5	45

#	ARTICLE	IF	CITATIONS
37	Compartmentalization of Immune Response and Microbial Translocation in Decompensated Cirrhosis. <i>Frontiers in Immunology</i> , 2019, 10, 69.	4.8	40
38	Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis. <i>Frontiers in Immunology</i> , 2019, 10, 476.	4.8	134
39	The G-protein coupled receptor ChemR23 determines smooth muscle cell phenotypic switching to enhance high phosphate-induced vascular calcification. <i>Cardiovascular Research</i> , 2019, 115, 1557-1566.	3.8	35
40	Orchestration of Tryptophanâ€Kynurenine Pathway, Acute Decompensation, and Acuteâ€onâ€Chronic Liver Failure in Cirrhosis. <i>Hepatology</i> , 2019, 69, 1686-1701.	7.3	80
41	Acute-on-Chronic Liver Failure, Human Serum Albumin, and Immune Modulation: The Beginning of an Exciting Adventure. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 633-636.	4.4	6
42	The soluble guanylate cyclase stimulator IWA€1973 prevents inflammation and fibrosis in experimental nonâ€alcoholic steatohepatitis. <i>British Journal of Pharmacology</i> , 2018, 175, 953-967.	5.4	53
43	Circulating <scp>CXCL</scp>10 in cirrhotic portal hypertension might reflect systemic inflammation and predict <scp>ACLF</scp> and mortality. <i>Liver International</i> , 2018, 38, 875-884.	3.9	35
44	Opposing Effects on Vascular Smooth Muscle Cell Proliferation and Macrophage-induced Inflammation Reveal a Protective Role for the Proresolving Lipid Mediator Receptor ChemR23 in Intimal Hyperplasia. <i>Frontiers in Pharmacology</i> , 2018, 9, 1327.	3.5	22
45	Systemic Inflammation and Acute-on-Chronic Liver Failure: Too Much, Not Enough. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018, 2018, 1-10.	1.9	55
46	Oxidized Albumin Triggers a Cytokine Storm in Leukocytes Through P38 Mitogenâ€Activated Protein Kinase: Role in Systemic Inflammation in Decompensated Cirrhosis. <i>Hepatology</i> , 2018, 68, 1937-1952.	7.3	70
47	Frontline Science: Specialized proresolving lipid mediators inhibit the priming and activation of the macrophage NLRP3 inflammasome. <i>Journal of Leukocyte Biology</i> , 2018, 105, 25-36.	3.3	72
48	Pro-resolving actions of SPM in adipose tissue biology. <i>Molecular Aspects of Medicine</i> , 2017, 58, 83-92.	6.4	33
49	The specialized proresolving lipid mediator maresin 1 protects hepatocytes from lipotoxic and hypoxiaâ€induced endoplasmic reticulum stress. <i>FASEB Journal</i> , 2017, 31, 5384-5398.	0.5	56
50	Association of a variant in the gene encoding for ERV1/ChemR23 with reduced inflammation in visceral adipose tissue from morbidly obese individuals. <i>Scientific Reports</i> , 2017, 7, 15724.	3.3	27
51	Editorialâ€Special issue of the 6th European Workshop on Lipid Mediators. <i>Prostaglandins and Other Lipid Mediators</i> , 2017, 133, 1-3.	1.9	0
52	Polymorphisms in the ILâ€1 gene cluster influence systemic inflammation in patients at risk for acuteâ€onâ€chronic liver failure. <i>Hepatology</i> , 2017, 65, 202-216.	7.3	39
53	Integrative microRNA profiling in alcoholic hepatitis reveals a role for microRNA-182 in liver injury and inflammation. <i>Gut</i> , 2016, 65, 1535-1545.	12.1	103
54	Systemic inflammation in decompensated cirrhosis: Characterization and role in acuteâ€onâ€chronic liver failure. <i>Hepatology</i> , 2016, 64, 1249-1264.	7.3	550

#	ARTICLE	IF	CITATIONS
55	Principles, Mechanisms of Action, and Future Prospects of Anti-inflammatory Drugs. , 2016, , 17-34.		6
56	Signaling and Immunoresolving Actions of Resolvin D1 in Inflamed Human Visceral Adipose Tissue. Journal of Immunology, 2016, 197, 3360-3370.	0.8	87
57	The Acute-on-Chronic Liver Failure Syndrome, or When the Innate Immune System Goes Astray. Journal of Immunology, 2016, 197, 3755-3761.	0.8	91
58	Pro-resolving mediators produced from EPA and DHA: Overview of the pathways involved and their mechanisms in metabolic syndrome and related liver diseases. European Journal of Pharmacology, 2016, 785, 133-143.	3.5	73
59	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
60	Role of bioactive lipid mediators in obese adipose tissue inflammation and endocrine dysfunction. Molecular and Cellular Endocrinology, 2016, 419, 44-59.	3.2	64
61	Prostaglandin E2 Exerts Multiple Regulatory Actions on Human Obese Adipose Tissue Remodeling, Inflammation, Adaptive Thermogenesis and Lipolysis. PLoS ONE, 2016, 11, e0153751.	2.5	98
62	Editorial. Prostaglandins and Other Lipid Mediators, 2015, 121, 1-3.	1.9	1
63	Aspirin in the 21st centuryâ€”common mechanisms of disease and their modulation by aspirin: a report from the 2015 scientific conference of the international aspirin foundation, 28 August, London, UK. Ecancermedalscience, 2015, 9, 581.	1.1	4
64	Inhibition of soluble epoxide hydrolase modulates inflammation and autophagy in obese adipose tissue and liver: Role for omega-3 epoxides. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 536-541.	7.1	185
65	Aplicaci3n de la secuenciaci3n masiva de nueva generaci3n al diagn3stico molecular de la hipercolesterolemia familiar. Revista Del Laboratorio Cl3nico, 2015, 8, 8-18.	0.1	0
66	Molecular interplay between 5/6 desaturases and long-chain fatty acids in the pathogenesis of non-alcoholic steatohepatitis. Gut, 2014, 63, 344-355.	12.1	107
67	Prostaglandin E <sub>2</sub> signals white-to-brown adipogenic differentiation. Adipocyte, 2014, 3, 290-296.	2.8	27
68	Resolvins, Specialized Proresolving Lipid Mediators, and Their Potential Roles in Metabolic Diseases. Cell Metabolism, 2014, 19, 21-36.	16.2	378
69	Resolvin D1 primes the resolution process initiated by calorie restriction in obesity-induced steatohepatitis. FASEB Journal, 2014, 28, 836-848.	0.5	97
70	Coordinate Functional Regulation between Microsomal Prostaglandin E Synthase-1 (mPGES-1) and Peroxisome Proliferator-activated Receptor 3 (PPAR3) in the Conversion of White-to-brown Adipocytes. Journal of Biological Chemistry, 2013, 288, 28230-28242.	3.4	72
71	Omega-3-derived mediators counteract obesity-induced adipose tissue inflammation. Prostaglandins and Other Lipid Mediators, 2013, 107, 77-84.	1.9	32
72	Cell-specific PPAR3 deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells. Journal of Hepatology, 2013, 59, 1045-1053.	3.7	91

#	ARTICLE	IF	CITATIONS
73	Diversity of lipid mediators in human adipose tissue depots. American Journal of Physiology - Cell Physiology, 2013, 304, C1141-C1149.	4.6	112
74	Resolution of inflammation in obesity-induced liver disease. Frontiers in Immunology, 2012, 3, 257.	4.8	67
75	Resolvin D1 and Resolvin D2 Govern Local Inflammatory Tone in Obese Fat. Journal of Immunology, 2012, 189, 2597-2605.	0.8	222
76	Natural killer cell recognition and killing of activated hepatic stellate cells. Gut, 2012, 61, 792-793.	12.1	8
77	An investigation of the resolution of inflammation (catabasis) in COPD. Respiratory Research, 2012, 13, 101.	3.6	19
78	New insights into the role of macrophages in adipose tissue inflammation and fatty liver disease: modulation by endogenous omega-3 fatty acid-derived lipid mediators. Frontiers in Immunology, 2011, 2, 49.	4.8	40
79	The 5-lipoxygenase/leukotriene pathway in obesity, insulin resistance, and fatty liver disease. Current Opinion in Clinical Nutrition and Metabolic Care, 2011, 14, 347-353.	2.5	52
80	Resolvin D1 and Its Precursor Docosahexaenoic Acid Promote Resolution of Adipose Tissue Inflammation by Eliciting Macrophage Polarization toward an M2-Like Phenotype. Journal of Immunology, 2011, 187, 5408-5418.	0.8	360
81	Role for PPAR $\gamma$ in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts. FASEB Journal, 2011, 25, 2538-2550.	0.5	325
82	The Role of Inflammatory Mediators in Liver Failure. , 2011, , 131-153.		4
83	Protection from hepatic lipid accumulation and inflammation by genetic ablation of 5-lipoxygenase. Prostaglandins and Other Lipid Mediators, 2010, 92, 54-61.	1.9	22
84	5-lipoxygenase deficiency reduces hepatic inflammation and tumor necrosis factor $\alpha$ -induced hepatocyte damage in hyperlipidemia-prone ApoE-null mice. Hepatology, 2010, 51, 817-827.	7.3	86
85	Disruption of the 12/15-lipoxygenase gene (Alox15) protects hyperlipidemic mice from nonalcoholic fatty liver disease. Hepatology, 2010, 52, 1980-1991.	7.3	59
86	Resolution of Adipose Tissue Inflammation. Scientific World Journal, The, 2010, 10, 832-856.	2.1	56
87	Resolution of Acute Inflammation and the Role of Lipid Mediators. Scientific World Journal, The, 2010, 10, 1553-1555.	2.1	5
88	5-Lipoxygenase Activating Protein Signals Adipose Tissue Inflammation and Lipid Dysfunction in Experimental Obesity. Journal of Immunology, 2010, 184, 3978-3987.	0.8	139
89	Resolvins, protectins and other lipid mediators in obesity-associated inflammatory disorders. Drug Discovery Today Disease Mechanisms, 2010, 7, e219-e225.	0.8	2
90	The pathogen receptor liver and lymph node sinusoidal endothelial cell C-type lectin is expressed in human Kupffer cells and regulated by PU.1. Hepatology, 2009, 49, 287-296.	7.3	40

#	ARTICLE	IF	CITATIONS
91	Obesity-induced insulin resistance and hepatic steatosis are alleviated by $\omega$ -3 fatty acids: a role for resolvins and protectins. <i>FASEB Journal</i> , 2009, 23, 1946-1957.	0.5	511
92	Increased susceptibility to exacerbated liver injury in hypercholesterolemic ApoE-deficient mice: potential involvement of oxysterols. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 296, G553-G562.	3.4	66
93	Regulatory effects of arachidonate 5-lipoxygenase on hepatic microsomal TG transfer protein activity and VLDL-triglyceride and apoB secretion in obese mice. <i>Journal of Lipid Research</i> , 2008, 49, 2513-2523.	4.2	45
94	Comparative Protection against Liver Inflammation and Fibrosis by a Selective Cyclooxygenase-2 Inhibitor and a Nonredox-Type 5-Lipoxygenase Inhibitor. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 323, 778-786.	2.5	52
95	New Approaches to the Modulation of the Cyclooxygenase-2 and 5-Lipoxygenase Pathways. <i>Current Topics in Medicinal Chemistry</i> , 2007, 7, 297-309.	2.1	53
96	The results in rodent models of atherosclerosis are not interchangeable. <i>Atherosclerosis</i> , 2007, 195, e85-e92.	0.8	55
97	Bradykinin Attenuates Hepatocellular Damage and Fibrosis in Rats With Chronic Liver Injury. <i>Gastroenterology</i> , 2007, 133, 2019-2028.	1.3	41
98	Gene expression profiling of renal dysfunction in rats with experimental cirrhosis. <i>Journal of Hepatology</i> , 2006, 45, 221-229.	3.7	3
99	Regulation of Cell Proliferation and Apoptosis by Bioactive Lipid Mediators. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2006, 1, 369-382.	1.6	33
100	A coding polymorphism in the 12-lipoxygenase gene is associated to essential hypertension and urinary 12(S)-HETE. <i>Kidney International</i> , 2006, 69, 526-530.	5.2	35
101	Changes in liver and plasma acetylcholinesterase in rats with cirrhosis induced by bile duct ligation. <i>Hepatology</i> , 2006, 43, 444-453.	7.3	38
102	New Insights into the Regulation of Liver Inflammation and Oxidative Stress. <i>Mini-Reviews in Medicinal Chemistry</i> , 2006, 6, 1321-1330.	2.4	30
103	Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA. <i>FASEB Journal</i> , 2006, 20, 2537-2539.	0.5	194
104	Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. <i>Hepatology</i> , 2005, 41, 579-587.	7.3	79
105	Reply:. <i>Hepatology</i> , 2005, 42, 238-238.	7.3	6
106	New Perspectives in the Modulation of the Eicosanoid Cascade in Inflammation. <i>Letters in Drug Design and Discovery</i> , 2005, 2, 391-402.	0.7	2
107	Pharmacological Intervention of Cyclooxygenase-2 and 5-Lipoxygenase Pathways. Impact on Inflammation and Cancer. <i>Current Pharmaceutical Design</i> , 2005, 11, 3431-3447.	1.9	83
108	The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPAR $\gamma$ activation. <i>FASEB Journal</i> , 2005, 19, 1120-1122.	0.5	129



#	ARTICLE	IF	CITATIONS
109	Inhibition of 5-lipoxygenase-activating protein abrogates experimental liver injury: role of Kupffer cells. <i>Journal of Leukocyte Biology</i> , 2005, 78, 871-878.	3.3	56
110	The selective cyclooxygenase-2 inhibitor celecoxib modulates the formation of vasoconstrictor eicosanoids and activates PPAR $\gamma$ . Influence of albumin. <i>Journal of Hepatology</i> , 2005, 42, 75-81.	3.7	34
111	Liver: The formation and actions of aspirin-triggered lipoxins. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2005, 73, 277-282.	2.2	12
112	5-Lipoxygenase (5-LO) is Involved in Kupffer Cell Survival. Possible Role of 5-LO Products in the Pathogenesis of Liver Fibrosis. <i>Comparative Hepatology</i> , 2004, 3, S19.	0.9	4
113	F2 isoprostane is already increased at the onset of type 1 diabetes mellitus: Effect of glycemic control. <i>Metabolism: Clinical and Experimental</i> , 2004, 53, 1118-1120.	3.4	33
114	Increased apoptosis dependent on caspase-3 activity in polymorphonuclear leukocytes from patients with cirrhosis and ascites. <i>Journal of Hepatology</i> , 2004, 41, 44-48.	3.7	26
115	Prostaglandins and other cyclooxygenase-dependent arachidonic acid metabolites and the kidney in liver disease. <i>Prostaglandins and Other Lipid Mediators</i> , 2003, 72, 19-33.	1.9	21
116	Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. <i>FASEB Journal</i> , 2003, 17, 1986-1995.	0.5	204
117	Inhibition of 5-lipoxygenase induces cell growth arrest and apoptosis in rat Kupffer cells: implications for liver fibrosis. <i>FASEB Journal</i> , 2003, 17, 1745-1747.	0.5	67
118	Cyclooxygenase-2 Biology. <i>Current Pharmaceutical Design</i> , 2003, 9, 2177-2190.	1.9	209
119	Renal Effects of Selective Cyclooxygenase Inhibition in Experimental Liver Disease. <i>Advances in Experimental Medicine and Biology</i> , 2003, 525, 133-136.	1.6	0
120	Aspirin (ASA) regulates 5-lipoxygenase activity and peroxisome proliferator-activated receptor $\gamma$ -mediated CINC $\beta$ release in rat liver cells: novel actions of lipoxin A4(LXA4) and ASA-triggered 15-Epi-LXA4. <i>FASEB Journal</i> , 2002, 16, 1937-1939.	0.5	58
121	Endogenous cannabinoids: A new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. <i>Gastroenterology</i> , 2002, 122, 85-93.	1.3	222
122	5-lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: A possible role of cysteinyl-leukotrienes. <i>Gastroenterology</i> , 2002, 122, 387-393.	1.3	96
123	Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites. <i>British Journal of Pharmacology</i> , 2002, 135, 891-900.	5.4	43
124	Aspirin-Triggered 15-Epi-Lipoxin A4 Biosynthesis in Rat Liver Cells. <i>Advances in Experimental Medicine and Biology</i> , 2002, 507, 199-209.	1.6	0
125	Increased Levels of 12(S)-HETE in Patients With Essential Hypertension. <i>Hypertension</i> , 2001, 37, 334-338.	2.7	89
126	5-lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor. <i>FASEB Journal</i> , 2001, 15, 2326-2336.	0.5	118



#	ARTICLE	IF	CITATIONS
127	Sodium in preascitic cirrhosis: please pass the salt. Gut, 2001, 49, 748-749.	12.1	0
128	Hepatocyte-derived cysteinyl leukotrienes modulate vascular tone in experimental cirrhosis. Gastroenterology, 2000, 119, 794-805.	1.3	69
129	Hepatocytes are a rich source of novel aspirin-triggered 15-epi-lipoxin A <sub>4</sub> . American Journal of Physiology - Cell Physiology, 1999, 277, C870-C877.	4.6	46
130	Vascular endothelial growth factor production in peritoneal macrophages of cirrhotic patients: Regulation by cytokines and bacterial lipopolysaccharide. Hepatology, 1999, 29, 1057-1063.	7.3	68
131	Atrial natriuretic peptide antagonizes endothelin-induced calcium increase and cell contraction in cultured human hepatic stellate cells. Hepatology, 1999, 30, 501-509.	7.3	30
132	Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites. Gastroenterology, 1999, 116, 1167-1175.	1.3	61
133	Smoking increases serum levels of transforming growth factor-beta in diabetic patients. Diabetes Care, 1999, 22, 1915-1916.	8.6	28
134	Altered biosynthesis of leukotrienes and lipoxins and host defense disorders in patients with cirrhosis and ascites. Gastroenterology, 1998, 115, 147-156.	1.3	63
135	Aspirin-Triggered Lipoxins (15-epi-LX) Are Generated by the Human Lung Adenocarcinoma Cell Line (A549) and Neutrophil Interactions and Are Potent Inhibitors of Cell Proliferation. Molecular Medicine, 1996, 2, 583-596.	4.4	183
136	Nitric oxide production in arterial vessels of cirrhotic rats. Hepatology, 1995, 21, 554-560.	7.3	88
137	Effect of upright posture and physical exercise on endogenous neurohormonal systems in cirrhotic patients with sodium retention and normal supine plasma renin, aldosterone, and norepinephrine levels. Hepatology, 1995, 22, 479-487.	7.3	41
138	Role of nitric oxide and prostacyclin in the control of renal perfusion in experimental cirrhosis. Hepatology, 1995, 22, 915-920.	7.3	65
139	Endothelin 1 does not play a major role in the homeostasis of arterial pressure in cirrhotic rats with ascites. Gastroenterology, 1995, 108, 1842-1848.	1.3	59
140	Aquaretic effect of the $\mu$ -opioid agonist RU 51599 in cirrhotic rats with ascites and water retention. Gastroenterology, 1995, 109, 217-223.	1.3	44
141	Antidiuretic Hormone and the Pathogenesis of Water Retention in Cirrhosis with Ascites. Seminars in Liver Disease, 1994, 14, 44-58.	3.6	85
142	Diagnosis of functional kidney failure of cirrhosis with Doppler sonography: Prognostic value of resistive index. Hepatology, 1994, 20, 839-844.	7.3	124
143	Renal effects of natriuretic peptide receptor blockade in cirrhotic rats with ascites. Hepatology, 1994, 20, 948-954.	7.3	60
144	Increased nitric oxide-dependent vasorelaxation in aortic rings of cirrhotic rats with ascites. Hepatology, 1994, 20, 1615-1621.	7.3	86

#	ARTICLE	IF	CITATIONS
145	Blunted natriuretic response to human urine extracts with Na <sup>+</sup> , K <sup>+</sup> -ATPase inhibiting activity in experimental cirrhosis. <i>Journal of Hepatology</i> , 1994, 20, 660-665.	3.7	1
146	Intracellular calcium concentration in vascular smooth muscle cells of rats with cirrhosis. <i>Journal of Hepatology</i> , 1994, 21, 521-526.	3.7	19
147	Brachial and femoral artery blood flow in cirrhosis: Relationship to kidney dysfunction. <i>Hepatology</i> , 1993, 17, 788-793.	7.3	136
148	Renal effects of acute isosorbide-5-mononitrate administration in cirrhosis. <i>Hepatology</i> , 1993, 17, 800-806.	7.3	63
149	Impaired responsiveness to angiotensin II in experimental cirrhosis: Role of nitric oxide. <i>Hepatology</i> , 1993, 18, 367-372.	7.3	142
150	Circulating levels of endothelin in cirrhosis. <i>Gastroenterology</i> , 1993, 104, 1485-1491.	1.3	198
151	Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. <i>Gastroenterology</i> , 1993, 105, 229-236.	1.3	820
152	Carbon tetrachloride induced cirrhosis in rats: A useful tool for investigating the pathogenesis of ascites in chronic liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1992, 7, 90-97.	2.8	70
153	Pathogenesis of arterial hypotension in cirrhotic rats with ascites: Role of endogenous nitric oxide. <i>Hepatology</i> , 1992, 15, 343-349.	7.3	201
154	Effect of V1-vasopressin receptor blockade on arterial pressure in conscious rats with cirrhosis and ascites. <i>Gastroenterology</i> , 1991, 100, 494-501.	1.3	78
155	Doses of endothelin have natriuretic effects in conscious rats with cirrhosis and ascites. <i>Kidney International</i> , 1991, 40, 182-187.	5.2	25
156	Temporal relationship between the decrease in arterial pressure and sodium retention in conscious spontaneously hypertensive rats with carbon tetrachloride-induced cirrhosis. <i>Hepatology</i> , 1991, 13, 585-589.	7.3	40
157	Natriuretic hormone activity in the urine of cirrhotic patients. <i>Hepatology</i> , 1990, 12, 467-475.	7.3	19
158	Blockade of the hydroosmotic effect of vasopressin normalizes water excretion in cirrhotic rats. <i>Gastroenterology</i> , 1989, 97, 1294-1299.	1.3	63